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Abstract
Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palpable
purpuric rash and frequently involving the renal system. We are the first group to clinically assess, critically analyse and
subsequently revise a nurse led monitoring pathway for this condition. A cohort of 102 children presenting with HSP to a
secondary/tertiary level UK paediatric hospital over a five year period, were monitored using a nurse led care pathway.
Using this cohort, the incidence (6.21 cases per 100,000 children per year) and natural disease course of HSP nephritis (46%
initial renal inflammation; 9% subsequent renal referral; 1% renal biopsy and immunosuppression) was determined. Older
patients were at higher risk of requiring a renal referral (renal referral 12.3 (8.4–13.5) years vs. normal outcome 6.0 (3.7–8.5)
years; p,0.01). A normal urinalysis on day 7 had a 97% (confidence interval 90 to 99%) negative predictive value in
predicting a normal renal outcome. Using this data and existing literature base, The Alder Hey Henoch Schonlein Purpura
Pathway was developed, a revised pathway for the screening of poor renal outcome in HSP. This is based on a six-month
monitoring period for all patients presenting with HSP, which importantly prioritises patients according to the urine findings
on day 7 and thus intensively monitors those at higher risk of developing nephritis. The pathway could be easily adapted for
use in different settings and resources. The introduction of a standardised pathway for the monitoring of HSP will facilitate
the implementation of disease registries to further our understanding of the condition and permit future clinical trials.
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Introduction
Henoch Schonlein Purpura (HSP) is the commonest systemic
vasculitis of childhood with a reported incidence of 10–20 cases per
100,000 children per year [1]. HSP can present at any age, but is
mostcommoninchildrenunderfive.Generallytheprognosisisgood,
with the exception of those with significant renal involvement [2].
The principal aim of HSP follow up is detecting persistent renal
inflammation, which undiagnosed, could progress to permanent
renal damage [3]. Due to the asymptomatic nature of HSP
associated nephritis, unlike all other associated complications,
most centres provide a program of regular urine and blood
pressure (BP) monitoring for up to 12 months. The long term risk
of permanent renal impairment in patients with minor urine
abnormalities is low (1.6% reported previously [2]). However, this
rises to 19.5% in children with nephrotic or nephritic features
[2,4]. A meta-analysis on the use of early corticosteroids in this
condition suggested some effect on the renal outcome [5] and
immunosuppressive treatments are used in severe cases, as they are
believed to preserve renal function, despite a paucity of
randomised controlled trials. Universal follow up for patients with
HSP imposes a financial burden on healthcare services and
increases parental anxiety and inconvenience. Its role remains
uncertain and there is need for standardised evidence based
monitoring.
A nurse led HSP renal monitoring care pathway has been
implemented at Alder Hey Children’s Hospital (UK) for over five
years. The first aim of this study was to describe the disease course
in a cohort of patients on this pathway, recording the occurrence
of proteinuria and the resolution of renal inflammation. The
second aim, using these data and previous published cohort data,
was to develop a revised pathway for the screening of HSP
associated nephritis.
Results
Subjects
Using the hospital coding system, 176 patients were identified
during June 2004 to February 2010, a 5.67-year period. Following
case note inspection 165 patients had a diagnosis of HSP, 61
patients were ineligible for further analysis, as the pathway data was
not available. Using the 165 cases presenting over 5.67 years, the
calculated incidence was 6.21 HSP cases per 100,000 Liverpool
children (aged 0–15 years), per year (Source: 2001 UK Census:
Standard Area Statistics (England and Wales)). Figure 1 outlines the
recruitment and subsequent follow up for the study cohort.
The median age was 6.3 (range 0.3–15.4; IQR 4.0–9.5) years
with 48% male gender and 90% Caucasian ethnicity. The median
length of follow up was 12 months. Those requiring renal referral
were significantly older than those with a normal renal outcome
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8.5) years; p,0.01).
Presenting features
Of 102 patients where pathway review took place, presenting
symptoms included: palpable purpuric rash (100%), arthralgia
(45%), joint swelling (19%), abdominal pain (9%), fever (5%),
lethargy (1%), bloody stools (1%), haematuria (1%), scrotal pain
(1%) and limp (1%). No patients were nephrotic, nephritic or had
an abnormal renal function at the initial diagnosis. Two patients
presented with a second recurrence of HSP with the first episode
being uncomplicated and before pathway implementation.
Hypertension
At diagnosis/presentation, 14% of patients were hypertensive,
including 10% with a BP .99
th centile. This hypertension was
unlikely recognised as it did not prompt further evaluation, 64% of
patients who presented with hypertension had a normal urinalysis,
28% had proteinuria ($1+) and one patient (7%) had mixed
proteinuria (1+) and haematuria (3+). Importantly, there were no
patientepisodesofhypertensionafterentrytothefollowuppathway
(day 7) in any child, including those who required medical review.
Initial Urinalysis
At diagnosis 53% (55/102) had a normal urinalysis, 37% had
isolated proteinuria, 2% had isolated haematuria (one macroscop-
ic) and 7% had mixed proteinuria and haematuria. 1 patient had
no urine result documented.
Monitoring pathway
At day 7 review, patients were triaged into follow up regimens, 80
patients started on thestandard pathway, asthey hadno evidence of
proteinuria at that time and 22 patients on the proteinuria pathway.
After 12 months follow up 13 patients developed proteinuria after
day 7, giving a total of 35 patients on the proteinuria pathway.
Overall 91 patients could be discharged after 12 months and 9
patients were (or had already been) referred to a paediatrician in
view of persistent urine abnormalities or meeting the exit criteria.
Normal urinalysis at presentation
Patients with a normal urinalysis at day 7 but who later
transferred to the proteinuria pathway (n=13) developed
abnormalities up to 6 months (day 168). In all patients presenting
with the first occurrence of an abnormal urinalysis after 1 month
(day 28), the proteinuria (1+) was an isolated episode with a
normal urine albumin:creatinine ratio and a normal outcome.
Within the group of patients with a normal urinalysis at day 7, two
required a renal referral, one of which transferred to the
proteinuria pathway before day 28, described in the renal
outcome section below, the second patient was referred at 12
months for persistent microscopic haematuria (1+), which resolved
by 14 months.
Figure 1. The HSP cohort - recruitment, follow up and outcome.
doi:10.1371/journal.pone.0029512.g001
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Nine patients from the study group met the primary outcome of
a medical referral, two of these had an early rise in UACR and
were referred within 3 months from diagnosis for nephrology
review (one of which started on the standard pathway described
above); the other seven patients had persistent proteinuria or
haematuria at 12 months. Four of these with persistent changes
remain under nephrology follow up with on going microscopic
urine abnormalities but normal renal function and normal blood
pressure. Out of the two patients with a raised urine protein level
exiting the pathway early, one developed nephrotic syndrome
within the first month following diagnosis and a renal biopsy
revealed grade III HSP nephritis according to the ISN
classification [6]; they required immunosuppression, angiotensin
converting enzyme (ACE) inhibition and a repeat biopsy seven
months later demonstrated improvement with grade II HSP
nephritis. They remain under nephrology review on ACE
inhibition with microscopic haematuria and proteinuria, but with
normal renal function and normotensive. The second patient had
a peak UACR of 408 mg/mmol at day 14, was referred to a
nephrologist with resolution of proteinuria over the subsequent
month. He remains under observation with a normal urinalysis
and normal blood pressure.
Positive and negative predictive values
Using the urinalysis results from day 7, the positive and negative
predictive values and sensitivity and specificity for a medical
referral were calculated (table 1). The positive predictive value of
the finding of proteinuria on urinalysis testing at day 7 and a renal
outcome was 32% (15 to 55%) and the negative predictive value
was 97% (90 to 99%) [7,8]. The sensitivity of the day seven
urinalysis and the need for a medical referral was 77.8% (45.3–
93.7%) and specificity 83.5% (74.6–89.8%).
Other clinical outcomes
Two patients required a rheumatology referral due to a
persistent purpuric rash, but the diagnosis was upheld.
Patients with missing pathway data
The hospital computerised appointment and results system was
searched for evidence of renal histology, reviews and abnormal
urinalysis or blood tests, for those patients with irretrievable
pathway data. There were no significant differences between the
group with missing pathway data and the study cohort with
regards to demographic data (age p=0.157, sex p=0.67, ethnicity
p=0.90) or renal outcome (p=0.055). From the 61 patients
excluded, one patient had undergone a renal biopsy revealing
grade III HSP nephropathy and two patients had seen a
nephrologist with recent discharge from follow up. The exact
details of these patients were unavailable and further conclusions
could not be established.
Discussion
This is the first study to our knowledge, to clinically evaluate,
critically appraise, and subsequently revise, a care pathway for the
monitoring of HSP nephritis. Our data, together with other studies,
demonstrates an overall low risk of HSP associated nephritis in an
unselected cohort of patients presenting with features of HSP, 91%
had a self-limitingdiseasecourse in ourseries.There havenow been
several cohorts describing this, together with the finding that
patients with HSP who present with or develop proteinuria are at
the greatest risk of renal complications [2,3,4,9,10,11,12,13,14,
15,16,17,18]. A stratified approach to monitoring which is robust
enough to allow early identification of the high-risk patients
balanced against the inconvenience to the family, resource
implications and burden to healthcare providers of prolonged or
costly follow up therefore seems appropriate.
The first aim of our study was to evaluate the rate of renal
involvement using a nurse led monitoring pathway. Our cohort
identified renal involvement in 46% of patients at presentation
with an eventual 9% requiring an exit from the nurse led follow up
(the primary outcome) and a discussion/review with a nephrologist
and 1% of patients requiring a renal biopsy and immunosuppres-
sive treatment. As with some other reports, we have identified
older children presenting with HSP at the highest risk of renal
involvement [19]. A stratified approach will allow focus on these
individuals.
The second aim of this study was to revise and update our
pathway using our data and the latest literature, to produce a
follow up regimen that is evidence based and could be adapted for
implementation in other institutions. Nurse led follow up has
become an acceptable and more cost effective method for
monitoring specific illnesses [20] and HSP screening could utilise
the expertise of paediatric nurses. Within the UK, responsibility of
HSP follow up is usually with the paediatric multidisciplinary
team. The availability of appropriate blood pressure cuffs, trained
phlebotomists, the expertise in alleviating parental anxiety, and a
close working relationship with the multidisciplinary team are
necessary to provide easy access to specialist care if needed.
The revised pathway, The Alder Hey Henoch Schonlein
Purpura Pathway, is outlined in figure 2 and we shall now discuss
the reasoning behind its formulation.
A meta-analysis by Narchi, confirmed that the current
recommended length of follow up should be for 6 months
regardless of the presenting clinical features or urinary findings [2],
in our series all patients presented with proteinuria before 6
months after the initial HSP diagnosis. We have revised our
pathway in agreement with this, to a 6-month monitoring period.
Urine dipstick testing is easily accessible, can be performed with
minimal training and is a good negative indicator in the absence of
proteinuria [21]. It is generally accepted that moderate to severe
proteinuria are clinical risk factors associated with a poor renal
outcome [2,18,22]. The exact value of proteinuria during the
acute period cannot predict the renal prognosis but the absence of
proteinuria is known to be a good prognostic marker [3]. This is
confirmed in our cohort where the acute urinalysis had an
excellent negative predictive value, 97% of patients with a normal
urinalysis would not require a renal referral. This finding will allow
more accurate, individualised patient/parent counselling with
regard to the likely renal consequences of HSP. We have used the
urine dipstick as a first line measure of proteinuria in our pathway
Table 1. The urinalysis (day 7) and the occurrence of a renal
outcome.
Proteinuria on
urinalysis
No protein on
urinalysis Total
Clinician referral 7 (True positive) 2 (False negative) 9
Discharged 15(False positive) 76 (True positive) 91
Total 22 78 100
Each patient diagnosed with HSP had a random urinalysis taken and
subsequent monitoring frequency determined on the presence or absence of
proteinuria.
doi:10.1371/journal.pone.0029512.t001
Alder Hey HSP Pathway
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urine dipstick is positive, further quantification of proteinuria is
required as specified in our primary investigations (table 2).
At day 7, all patients will begin the revised monitoring. This
review is vital for provision of hand held records and parent
education. At this point, patients are triaged into either a standard
or more intensive (‘proteinuria’) follow up regimen. The revised
pathway ensures patients with a normal urinalysis receive a less
intensive follow up, but with a safeguard to convert onto the more
intensive monitoring if proteinuria develops. In the revised
pathway, decisions based on urinalysis should utilise early morning
samples. Those who develop proteinuria in the first month are at
the highest risk of renal complications, the risk of developing
significant proteinuria after 1 month was extremely low in our
series. Monitoring after this time point in patients with normal
urinalysis is therefore less frequent until 6 months is complete.
Figure 2. The Alder Hey Henoch Schonlein Purpura pathway - demonstrating follow up stratified according to the presence of
proteinuria at the day 7 review.
doi:10.1371/journal.pone.0029512.g002
Alder Hey HSP Pathway
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triaged to the more intensive follow up with reviews fortnightly in
the first month after diagnosis, then monthly until 4 months then a
subsequent visit at 6 months. The intervals have been carefully
selected using the knowledge that patients who develop nephrotic
or nephritic features are at greatest risk of a poor renal outcome
and that these features are likely to present within the first few
months. At each visit if proteinuria is present primary investiga-
tions are required and the results will be assessed to see if the
clinical features meet the specified exit criteria and warrant
secondary investigations (table 2) and same day medical review. In
either arm of the pathway if the urinalysis and blood pressure has
remained or becomes normal children can be discharged at 6
months.
The exit criteria in the pathway, include hypertension,
increased urine albumin:creatinine ratio, reduced serum albumin,
reduced glomerular filtration rate and persistent macroscopic
haematuria (figure 2). Hypertension has not clearly been linked to
a poorer outcome in patients with HSP nephritis however it will
require treatment and further investigation and so it is important
to identify and act accordingly. In line with current best practice
confirmation of hypertension should include measurement using a
manual sphygmomanometer repeated on three separate occasions
[2]. The rate of hypertension at diagnosis in our series should be
interpreted with caution, repeat measurements over several days
were not made, data was retrospectively reviewed and initial
measurements utilised an oscillometric device. However we have
demonstrated a rarity of hypertension during the monitoring
period. Further studies specifically focused on evaluating hyper-
tension, particularly during the acute inflammatory period in HSP,
are required.
The presence of proteinuria is a very important exit criterion as
it is the marker most commonly correlated with the renal
prognosis. Within the exit criteria, we have used the urine
albumin:creatinine ratio as a measure of proteinuria as it is
sufficiently related to 24 hour protein levels and more convenient
for paediatric practice [23]. The defined cut off values have been
based on previous cohort data which identified patients with
moderate to severe proteinuria at greater risk of poor renal
outcome [22,24] and so we require all patients with a UACR
between 100–200 mg/mmol with an increasing trend and those
with a UACR.200 mg/mmol to immediately exit from the
pathway for further investigation and management in liaison with
a paediatric nephrologist. Those patients with a UACR below
these set values, whilst undeniably having significant proteinuria,
continue to be monitored on the pathway as there is a high rate of
spontaneous resolution (27 out of 35 on our proteinuria pathway
resolved) and a lack of evidence demonstrating a poor renal
outcome. Serum albumin levels ,35 g/dL will assist with
identifying nephrotic patients and require exit from the pathway
and a medical review.
Reduced glomerular filtration rate is linked to a worse long-term
renal prognosis [24,25]. Early identification of impaired renal
function is an important part of our pathway. Haematuria is
commonly present in HSP nephritis and usually runs a benign
course when isolated [24]. Macroscopic haematuria for more than
7 days in our cohort was rare and would require further
investigation to explore differential diagnoses.
In summary the stated pathway exit criteria are relatively rare,
require secondary investigation (table 2) and medical review.
These features identify children who should be discussed with a
nephrologist and considered for histological evaluation and
immunosuppressive intervention. Future validation of the exit
criteria is required and may provide a good opportunity for
identifying patients for entry into future trials [26,27].
HSP screening programs vary greatly across the country and
around the world. Previously, Tizard was one of the first authors
to describe a recommended pathway for the follow up of patients
with HSP which triaged patients to additional investigations
according to proteinuria, however this pathway still required
frequent reviews for patients with normal urine findings [28]. We
have attempted to balance screening for renal involvement against
the inconvenience to the majority of patients who are at low risk of
a poor renal outcome using our data and the best available
evidence, whilst maintaining a six-month monitoring period in all
patients due to the limitations of our study. In addition to
producing a low cost and more convenient regimen, a standard-
ised follow up would facilitate randomised controlled trials to
assess the most appropriate therapy for this condition.
Limitations of this study include regionality, sample size and
missing datasets. Although not statistically significant, there was a
tendency for more renal involvement in case notes available for
inclusion in this manuscript. Despite this, it has clearly highlighted
the need for larger, multi-centre studies to improve our
understanding of HSP. Importantly, future prospective, larger,
representative studies would need to assess the strength of this
revised nurse-led pathway. In addition, clinical trials are urgently
needed to assess the effect of treatment interventions. A
standardised approach to HSP and the development of national
and international HSP registries will improve our understanding
and management of this childhood vasculitis.
In summary, unlike all other complications of HSP, nephritis is
typically asymptomatic and requires active screening. This study
provides important follow up data on the natural course of HSP
associated nephritis. Using these data, we have clinically
evaluated, critically appraised and subsequently revised the
evidence based monitoring regimen for patients with HSP,
producing the Alder Hey Henoch Schonlein Purpura pathway.
Table 2. Primary investigations for any case of proteinuria
(urine dipstick $1+) and secondary investigations for patients
meeting the predefined exit criteria, along with same day
medical review.
Primary investigations
Urea & electrolytes
Creatinine
Serum albumin
Urine albumin:creatinine ratio
Urine microscopy
Secondary investigations
Anti streptococcal titre (ASOT)
Antinuclear antibody (ANA)
Double stranded DNA (dsDNA)
Anti-neutrophil cytoplasmic antibody (ANCA)
Complement profile - C3, C4
Full blood count
Clotting
Erythrocyte sedimentation rate (ESR)
C reactive protein (CRP)
Immunoglobulin profile
Renal Ultrasound
doi:10.1371/journal.pone.0029512.t002
Alder Hey HSP Pathway
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achievable in a variety of settings, including some resource poor
countries, and would facilitate future studies.
Methods
HSP pathway
Alder Hey Children’s Hospital (UK) provides secondary care to
children with HSP presenting to Accident and Emergency or via
the family doctor, and tertiary care to children with renal
involvement, either identified during monitoring or referred from
other centres. A nurse led care pathway for HSP follow up was
formulated based on best evidence and practice in 2004
[3,11,29,30]. Children are diagnosed by the attending clinician
according to the ACR classification criteria [31], following
baseline investigations, and then referred to the nurse led pathway
via an internal computerised system. Initial follow up review is
within seven days of diagnosis (referred to throughout as ‘day 7
review’) and involves urinalysis for dipstick testing (Roche), blood
pressure (BP) measurement using an oscillometric devise (Dina-
map, Newport, USA) and parent education. Hand held records
and written information are provided with hospital contact
information and an open door policy. At initial review (day 7),
children are triaged into a ‘‘standard’’ or ‘‘proteinuria’’ pathway
according to the urine dipstick result. If a patient does not attend, a
letter is sent asking the parents to arrange another appointment. A
failure to reply, results in discharge and responsible consultant and
family doctor being informed.
On the standard pathway (seen on day 7, day 14, 1 month, 3
month, 6 month, 12 month), each review consists of BP
measurement and urinalysis. If proteinuria develops (defined as
$1+) at any time point additional primary investigations are
performed (table 2) and patients then transfer to the proteinuria
pathway. Patients on the proteinuria pathway are seen more
frequently (seen on day 7, day 14, 1 month, 2 month, 3 month, 4
month, 6 month, 12 month). At 12 months, patients with no urine
or BP abnormalities are discharged. Those with proteinuria or
haematuria are referred to a paediatrician. If a patient meets the
predefined ‘exit criteria’ at any stage - hypertension, urine
albumin:creatinine ratio (UACR) .200 mg/mmol, macroscopic
haematuria .28 days, serum albumin ,30 g/dl, reduced
estimated glomerular filtration rate (GFR) ,80 ml/min/m
2 (using
the Schwartz formula [32]) - they leave the nurse led pathway and
receive a same day medical review with secondary investigations
(table 2) and discussion with a paediatric nephrologist.
Study Case Retrieval and Eligibility
Patients were identified using the hospital diagnostic coding
system. Demographic and outcome data were recorded. All cases
were included if they had undergone follow up on the specific
pathway during the study period. Patients presenting with a
second occurrence of HSP were treated in the same manner as
those with a first episode of disease. Exclusion criteria included
those patients without a diagnosis of HSP, patients with
irretrievable pathway data and tertiary referrals for HSP nephritis
already diagnosed in another centre (to ensure an unselected HSP
cohort). To facilitate clinical data collection a standardised
proforma was used.
A priori definition of hypertension and proteinuria/haematuria
were used. Hypertension was defined as a systolic BP reading
.95
th centile for the child’s age, sex and height [33]. Significant
proteinuria/haematuria was defined as $1+ on random urinalysis.
Outcomes
The primary outcome for this study was the need to exit the
nurse led pathway either due to persistent proteinuria or
haematuria at 12 months or due to fulfilment of the earlier exit
criteria, and thus prompting medical review at an earlier time
point.
Statistical analysis
Demographic data were analysed for eligible patients. Patients
were described according to the presenting features, evolving renal
features and renal outcome after 12 months follow up. Statistics
Package for Social Sciences (SPSS Ltd, USA) version 18.0 was
used. Probability (‘p’) values ,0.05 were considered significant.
Results are presented as median values (interquartile ranges).
Positive and negative predictive values (confidence intervals) and
specificity and sensitivity (confidence intervals) were calculated
using the day 7 urinalysis as a screening tool to predict patients
who will develop renal involvement and require a medical review.
Ethical review
This study assessed current clinical practice and therefore, an
ethical review was not necessary under UK National Health
Service (NHS) research governance arrangements.
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